Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 104 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10425
Sealed predictions
- SLC25A20 in dopamine neurons, braak+0.28 (p 0.472) → -0.58 (p 0.104)receipt 10432
Swarm cases
receipt 10432: SLC25A20 in dopamine neurons, braak
- power
- full sample -0.18 (p 0.465, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.429, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.471, n 18). could be the mix.
- skeptic
- leave-one-out range -0.28 to -0.07, sign flips 0; without severely affected donors -0.18 (p 0.465, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0072, n 18) vs -0.18 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC25A20 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC25A20 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 2.1e-4)
Receipts
loading the receipts